Skip to main content
Erschienen in: Annals of Nuclear Medicine 3/2022

04.02.2022 | Original Article

I-124 PET/CT image-based dosimetry in patients with differentiated thyroid cancer treated with I-131: correlation of patient-specific lesional dosimetry to treatment response

verfasst von: Donika Plyku, Robert F. Hobbs, Di Wu, Carlos Garcia, George Sgouros, Douglas Van Nostrand

Erschienen in: Annals of Nuclear Medicine | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The objective of this study is to evaluate the lesion absorbed dose (AD), biological effective dose (BED), and equivalent uniform dose (EUD) to clinical–response relationship in lesional dosimetry for 131I therapy.

Methods

Nineteen lesions in four patients with metastatic differentiated thyroid cancer (DTC) were evaluated. The patients underwent PET/CT imaging at 2 h, 24 h, 48 h, 72 h, and 96 h post administration of ~ 33–65 MBq (0.89–1.76 mCi) of 124I before undergoing 131I therapy. The 124I PET/CT images were used to perform dosimetry calculations for 131I therapy. Lesion dose–rate values were calculated using the time–activity data and integrated over the measured time points to obtain AD and BED. The Geant4 toolkit was used to run Monte Carlo on spheres the same size as the lesions to estimate EUD. The lesion AD, BED, and EUD values were correlated with response data (i.e. change in lesion size pre- and post-therapy): complete response (CR, i.e. disappearance of the lesion), partial response (PR, i.e. any decrease in lesion length), stable disease (SD, i.e., no change in length), and progressive disease (PD, i.e., any increase in length).

Results

The lesion responses were CR and PR (58%, 11/19 lesions), SD (21%, 4/19), and PD (21%, 4/19). For CR and PR lesions, the ADs, BEDs and EUDs were > 75 Gy for 82% (9/11) and < 75 Gy for 18% (2/11). The ADs and BEDs were < 75 Gy for SD and PD lesions.

Conclusion

By performing retrospective dosimetry calculations for 131I therapy based on 124I PET/CT imaging, we evaluated the correlation of three dosimetric quantities to lesional response. When lesion AD, BED, and EUD values were > 75 Gy, 47% (9/19) of the lesions had a CR or PR. The AD, BED, and EUD values for SD and PD lesions were < 75 Gy. The data presented herein suggest that the greater the lesion AD, BED, and/or EUD, the higher the probability of a therapeutic response to 131I therapy.
Literatur
1.
Zurück zum Zitat Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. PubMedPubMedCentralCrossRef Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. PubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Van Nostrand D, Atkins F, Yeganeh F, Acio E, Bursaw R, Wartofsky L. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid. 2002;12(2):121–34. PubMedCrossRef Van Nostrand D, Atkins F, Yeganeh F, Acio E, Bursaw R, Wartofsky L. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid. 2002;12(2):121–34. PubMedCrossRef
3.
Zurück zum Zitat Atkins F, Van Nostrand D, Wartofsky L. Dosimetrically determined prescribed activity of I-131 for the treatment of metastatic differentiated thyroid cancer. In: Wartofsky L, Van Nostrand D, editors. Thyroid cancer: a comprehensive guide to clinical management. Berlin: Springer; 2016. p. 635–50. CrossRef Atkins F, Van Nostrand D, Wartofsky L. Dosimetrically determined prescribed activity of I-131 for the treatment of metastatic differentiated thyroid cancer. In: Wartofsky L, Van Nostrand D, editors. Thyroid cancer: a comprehensive guide to clinical management. Berlin: Springer; 2016. p. 635–50. CrossRef
4.
Zurück zum Zitat Benua RS, Cicale NR, Sonenberg M, Rawson R. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Therapy Nucl Med. 1962;87:171–82. Benua RS, Cicale NR, Sonenberg M, Rawson R. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Therapy Nucl Med. 1962;87:171–82.
5.
Zurück zum Zitat Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med. 2003;44(3):451–6. PubMed Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med. 2003;44(3):451–6. PubMed
6.
Zurück zum Zitat Van Nostrand D, Atkins F, Moreau S, Aiken M, Kulkarni K, Wu JS, et al. Utility of the radioiodine whole-body retention at 48 hours for modifying empiric activity of 131-iodine for the treatment of metastatic well-differentiated thyroid carcinoma. Thyroid. 2009;19(10):1093–8. PubMedCrossRef Van Nostrand D, Atkins F, Moreau S, Aiken M, Kulkarni K, Wu JS, et al. Utility of the radioiodine whole-body retention at 48 hours for modifying empiric activity of 131-iodine for the treatment of metastatic well-differentiated thyroid carcinoma. Thyroid. 2009;19(10):1093–8. PubMedCrossRef
7.
Zurück zum Zitat Thomas SR, Maxon HR, Kereiakes JG. In vivo quantitation of lesion radioactivity using external counting methods. Med Phys. 1976;3(4):253–5. CrossRef Thomas SR, Maxon HR, Kereiakes JG. In vivo quantitation of lesion radioactivity using external counting methods. Med Phys. 1976;3(4):253–5. CrossRef
8.
Zurück zum Zitat Benua RS. A method and rationale for treating metastatic thyroid carcinoma with the largest safe dose of I-131. Front Thyroidol. 1986, pp. 1317–1321. Benua RS. A method and rationale for treating metastatic thyroid carcinoma with the largest safe dose of I-131. Front Thyroidol. 1986, pp. 1317–1321.
9.
Zurück zum Zitat Lassmann M, Hänscheid H, Verburg F, Luster M. The use of dosimetry in the treatment of differentiated thyroid cancer. Q J Nucl Med Mol Imaging. 2011;55(2):107–15. PubMed Lassmann M, Hänscheid H, Verburg F, Luster M. The use of dosimetry in the treatment of differentiated thyroid cancer. Q J Nucl Med Mol Imaging. 2011;55(2):107–15. PubMed
10.
Zurück zum Zitat Hobbs RF, Wahl RL, Lodge MA, Javadi MS, Cho SY, Chien DT, et al. 124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison. J Nucl Med. 2009;50(11):1844–7. PubMedCrossRef Hobbs RF, Wahl RL, Lodge MA, Javadi MS, Cho SY, Chien DT, et al. 124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison. J Nucl Med. 2009;50(11):1844–7. PubMedCrossRef
11.
Zurück zum Zitat Dewaraja YK, Schipper MJ, Roberson PL, Wilderman SJ, Amro H, Regan DD, et al. 131I-tositumomab radioimmunotherapy: Initial tumor dose–response results using 3-dimensional dosimetry including radiobiologic modeling. J Nucl Med. 2010;51(7):1155–62. PubMedCrossRef Dewaraja YK, Schipper MJ, Roberson PL, Wilderman SJ, Amro H, Regan DD, et al. 131I-tositumomab radioimmunotherapy: Initial tumor dose–response results using 3-dimensional dosimetry including radiobiologic modeling. J Nucl Med. 2010;51(7):1155–62. PubMedCrossRef
12.
Zurück zum Zitat Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen I-W, Sperling MI, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. New Engl J Med. 1983;309(16):937–41. PubMedCrossRef Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen I-W, Sperling MI, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. New Engl J Med. 1983;309(16):937–41. PubMedCrossRef
13.
Zurück zum Zitat Jentzen W, Hoppenbrouwers J, van Leeuwen P, van der Velden D, van de Kolk R, Poeppel TD, et al. Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging. J Nucl Med. 2014;55(11):1759–65. PubMedCrossRef Jentzen W, Hoppenbrouwers J, van Leeuwen P, van der Velden D, van de Kolk R, Poeppel TD, et al. Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging. J Nucl Med. 2014;55(11):1759–65. PubMedCrossRef
14.
Zurück zum Zitat Wierts R, Brans B, Havekes B, Kemerink GJ, Halders SG, Schaper NN, et al. Dose–response relationship in differentiated thyroid cancer patients undergoing radioiodine treatment assessed by means of 124I PET/CT. J Nucl Med. 2016;57(7):1027–32. PubMedCrossRef Wierts R, Brans B, Havekes B, Kemerink GJ, Halders SG, Schaper NN, et al. Dose–response relationship in differentiated thyroid cancer patients undergoing radioiodine treatment assessed by means of 124I PET/CT. J Nucl Med. 2016;57(7):1027–32. PubMedCrossRef
15.
Zurück zum Zitat Cristy M, Eckerman K. Specific absorbed fractions of energy at various ages from internal photon sources: 1, methods. Oak Ridge: Oak Ridge National Lab; 1987. Cristy M, Eckerman K. Specific absorbed fractions of energy at various ages from internal photon sources: 1, methods. Oak Ridge: Oak Ridge National Lab; 1987.
16.
Zurück zum Zitat Prideaux AR, Song H, Hobbs RF, He B, Frey EC, Ladenson PW, et al. Three-dimensional radiobiologic dosimetry: Application of radiobiologic modeling to patient-specific 3-dimensional imaging–based internal dosimetry. J Nucl Med. 2007;48(6):1008–16. PubMedCrossRef Prideaux AR, Song H, Hobbs RF, He B, Frey EC, Ladenson PW, et al. Three-dimensional radiobiologic dosimetry: Application of radiobiologic modeling to patient-specific 3-dimensional imaging–based internal dosimetry. J Nucl Med. 2007;48(6):1008–16. PubMedCrossRef
17.
Zurück zum Zitat Plyku D, Hobbs RF, Huang K, Atkins F, Garcia C, Sgouros G, et al. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in 124I PET/CT–based dosimetry for 131I therapy of metastatic differentiated thyroid cancer. J Nucl Med. 2017;58(7):1146–54. PubMedPubMedCentralCrossRef Plyku D, Hobbs RF, Huang K, Atkins F, Garcia C, Sgouros G, et al. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in 124I PET/CT–based dosimetry for 131I therapy of metastatic differentiated thyroid cancer. J Nucl Med. 2017;58(7):1146–54. PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet no 21: a generalized schema for radiopharmaceutical dosimetry: standardization of nomenclature. J Nucl Med. 2009;50(3):477–84. PubMedCrossRef Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet no 21: a generalized schema for radiopharmaceutical dosimetry: standardization of nomenclature. J Nucl Med. 2009;50(3):477–84. PubMedCrossRef
19.
Zurück zum Zitat Plyku D, Lodge M, Van Nostrand D, Sgouros G, Hobbs R. Small volume activity quantification method for absorbed dose calculations. J Nucl Med. 2019;60(supplement 1):1135. Plyku D, Lodge M, Van Nostrand D, Sgouros G, Hobbs R. Small volume activity quantification method for absorbed dose calculations. J Nucl Med. 2019;60(supplement 1):1135.
20.
Zurück zum Zitat Hobbs R, Jentzen W, Bockisch A, Sgouros G. Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET. Q J Nucl Med Mol Imaging. 2013;57(1):79. PubMedPubMedCentral Hobbs R, Jentzen W, Bockisch A, Sgouros G. Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET. Q J Nucl Med Mol Imaging. 2013;57(1):79. PubMedPubMedCentral
21.
22.
Zurück zum Zitat Hobbs RF, Wahl RL, Frey EC, Kasamon Y, Song H, Huang P, et al. Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin lymphoma. J Nucl Med. 2013;54(9):1535–42. PubMedCrossRef Hobbs RF, Wahl RL, Frey EC, Kasamon Y, Song H, Huang P, et al. Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin lymphoma. J Nucl Med. 2013;54(9):1535–42. PubMedCrossRef
23.
Zurück zum Zitat Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. B J Radiol. 1985;58(690):515–28. CrossRef Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. B J Radiol. 1985;58(690):515–28. CrossRef
24.
Zurück zum Zitat Baechler S, Hobbs RF, Prideaux AR, Wahl RL, Sgouros G. Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. Med Phys. 2008;35(3):1123–34. PubMedCrossRef Baechler S, Hobbs RF, Prideaux AR, Wahl RL, Sgouros G. Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. Med Phys. 2008;35(3):1123–34. PubMedCrossRef
25.
Zurück zum Zitat Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. B J Radiol. 1989;62(740):679–94. CrossRef Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. B J Radiol. 1989;62(740):679–94. CrossRef
26.
Zurück zum Zitat Millar WT. Application of the linear-quadratic model with incomplete repair to radionuclide directed therapy. Br J Radiol. 1991;64(759):242–51. PubMedCrossRef Millar WT. Application of the linear-quadratic model with incomplete repair to radionuclide directed therapy. Br J Radiol. 1991;64(759):242–51. PubMedCrossRef
27.
Zurück zum Zitat Brenner DJ, Hlatky L, Hahnfeldt P, Huang Y, Sachs R. The linear-quadratic model and most other common radiobiological models result in similar predictions of time-dose relationships. Radiat Res. 1998;150(1):83–91. PubMedCrossRef Brenner DJ, Hlatky L, Hahnfeldt P, Huang Y, Sachs R. The linear-quadratic model and most other common radiobiological models result in similar predictions of time-dose relationships. Radiat Res. 1998;150(1):83–91. PubMedCrossRef
28.
Zurück zum Zitat Van Leeuwen C, Oei A, Crezee J, Bel A, Franken N, Stalpers L, et al. The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. Rad Oncol. 2018;13(1):1–11. Van Leeuwen C, Oei A, Crezee J, Bel A, Franken N, Stalpers L, et al. The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. Rad Oncol. 2018;13(1):1–11.
29.
Zurück zum Zitat Gaussen A, Legal J-D, Beron-Gaillard N, Laplanche A, Travagli J-P, Caillou B, et al. Radiosensitivity of human normal and tumoral thyroid cells using fluorescence in situ hybridization and clonogenic survival assay. Int J Radiat Oncol Biol Phys. 1999;44(3):683–91. PubMedCrossRef Gaussen A, Legal J-D, Beron-Gaillard N, Laplanche A, Travagli J-P, Caillou B, et al. Radiosensitivity of human normal and tumoral thyroid cells using fluorescence in situ hybridization and clonogenic survival assay. Int J Radiat Oncol Biol Phys. 1999;44(3):683–91. PubMedCrossRef
30.
Zurück zum Zitat Challeton C, Branea F, Schlumberger M, Gaillard N, de Vathaire F, Badie C, et al. Characterization and radiosensitivity at high or low dose rate of four cell lines derived from human thyroid tumors. Int J Radiat Oncol Biol Phys. 1997;37(1):163–9. PubMedCrossRef Challeton C, Branea F, Schlumberger M, Gaillard N, de Vathaire F, Badie C, et al. Characterization and radiosensitivity at high or low dose rate of four cell lines derived from human thyroid tumors. Int J Radiat Oncol Biol Phys. 1997;37(1):163–9. PubMedCrossRef
31.
Zurück zum Zitat Bodey R, Flux G, Evans P. Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose. Cancer Biother Radiopharm. 2003;18(1):89–97. PubMedCrossRef Bodey R, Flux G, Evans P. Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose. Cancer Biother Radiopharm. 2003;18(1):89–97. PubMedCrossRef
32.
Zurück zum Zitat Sgouros G, Hobbs RF, Atkins FB, Van Nostrand D, Ladenson PW, Wahl RL. Three-dimensional radiobiological dosimetry (3D-RD) with 124 I PET for 131 I therapy of thyroid cancer. Eur J Nucl Med Mol Imaging. 2011;38(1):41–7. CrossRef Sgouros G, Hobbs RF, Atkins FB, Van Nostrand D, Ladenson PW, Wahl RL. Three-dimensional radiobiological dosimetry (3D-RD) with 124 I PET for 131 I therapy of thyroid cancer. Eur J Nucl Med Mol Imaging. 2011;38(1):41–7. CrossRef
33.
Zurück zum Zitat Agostinelli S, Allison J, Ka A, Apostolakis J, Araujo H, Arce P, et al. GEANT4—a simulation toolkit. Nucl Instrum Methods Phys Res Sect A. 2003;506(3):250–303. CrossRef Agostinelli S, Allison J, Ka A, Apostolakis J, Araujo H, Arce P, et al. GEANT4—a simulation toolkit. Nucl Instrum Methods Phys Res Sect A. 2003;506(3):250–303. CrossRef
34.
Zurück zum Zitat Chalian H, Töre HG, Horowitz JM, Salem R, Miller FH, Yaghmai V. Radiologic assessment of response to therapy: comparison of RECIST versions 1.1 and 1.0. Radiographics. 2011;31(7):2093–105. PubMedCrossRef Chalian H, Töre HG, Horowitz JM, Salem R, Miller FH, Yaghmai V. Radiologic assessment of response to therapy: comparison of RECIST versions 1.1 and 1.0. Radiographics. 2011;31(7):2093–105. PubMedCrossRef
35.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. PubMedCrossRef Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. PubMedCrossRef
36.
Zurück zum Zitat Van Nostrand D, Hobbs R, Atkins FB, Sgouros G. 124 I in differentiated thyroid cancer. In: Wartofsky L, Van Nostrand D, editors. Thyroid cancer: a comprehensive guide to clinical management. Berlin: Springer; 2016. p. 973–89. CrossRef Van Nostrand D, Hobbs R, Atkins FB, Sgouros G. 124 I in differentiated thyroid cancer. In: Wartofsky L, Van Nostrand D, editors. Thyroid cancer: a comprehensive guide to clinical management. Berlin: Springer; 2016. p. 973–89. CrossRef
37.
Zurück zum Zitat Freudenberg LS, Jentzen W, Petrich T, Frömke C, Marlowe RJ, Heusner T, et al. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124 I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging. 2010;37(12):2267–76. PubMedCrossRef Freudenberg LS, Jentzen W, Petrich T, Frömke C, Marlowe RJ, Heusner T, et al. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124 I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging. 2010;37(12):2267–76. PubMedCrossRef
38.
Zurück zum Zitat Khorjekar GR, Van Nostrand D, Garcia C, O’Neil J, Moreau S, Atkins FB, et al. Do negative 124I pretherapy positron emission tomography scans in patients with elevated serum thyroglobulin levels predict negative 131I posttherapy scans? Thyroid. 2014;24(9):1394–9. PubMedPubMedCentralCrossRef Khorjekar GR, Van Nostrand D, Garcia C, O’Neil J, Moreau S, Atkins FB, et al. Do negative 124I pretherapy positron emission tomography scans in patients with elevated serum thyroglobulin levels predict negative 131I posttherapy scans? Thyroid. 2014;24(9):1394–9. PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Senthamizhchelvan S, Hobbs RF, Song H, Frey EC, Zhang Z, Armour E, et al. Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma. J Nucl Med. 2012;53(2):215–24. PubMedCrossRef Senthamizhchelvan S, Hobbs RF, Song H, Frey EC, Zhang Z, Armour E, et al. Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma. J Nucl Med. 2012;53(2):215–24. PubMedCrossRef
40.
Zurück zum Zitat Maxon HR 3rd, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS, Smith H, Cummings D, Aden MD. Radioiodine-131 therapy for well-differentiated thyroid cancer—a quantitative radiation dosimetric approach:outcome and validation in 85 patients. J Nucl Med. 1992;33(6):1132–6. PubMed Maxon HR 3rd, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS, Smith H, Cummings D, Aden MD. Radioiodine-131 therapy for well-differentiated thyroid cancer—a quantitative radiation dosimetric approach:outcome and validation in 85 patients. J Nucl Med. 1992;33(6):1132–6. PubMed
41.
Zurück zum Zitat Gear JI, Cox MG, Gustafsson J, Gleisner KS, Murray I, Glatting G, et al. EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations. Eur J Nucl Med Mol Imaging. 2018;45(13):2456–74. PubMedPubMedCentralCrossRef Gear JI, Cox MG, Gustafsson J, Gleisner KS, Murray I, Glatting G, et al. EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations. Eur J Nucl Med Mol Imaging. 2018;45(13):2456–74. PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Van Nostrand D. Radioiodine refractory differentiated thyroid cancer: time to update the classifications. Thyroid. 2018;28(9):1083–93. PubMedCrossRef Van Nostrand D. Radioiodine refractory differentiated thyroid cancer: time to update the classifications. Thyroid. 2018;28(9):1083–93. PubMedCrossRef
Metadaten
Titel
I-124 PET/CT image-based dosimetry in patients with differentiated thyroid cancer treated with I-131: correlation of patient-specific lesional dosimetry to treatment response
verfasst von
Donika Plyku
Robert F. Hobbs
Di Wu
Carlos Garcia
George Sgouros
Douglas Van Nostrand
Publikationsdatum
04.02.2022
Verlag
Springer Singapore
Erschienen in
Annals of Nuclear Medicine / Ausgabe 3/2022
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-021-01655-y

Weitere Artikel der Ausgabe 3/2022

Annals of Nuclear Medicine 3/2022 Zur Ausgabe